ClinicalTrials.gg
CompletedNCT00963846Updated Mar 1, 2013

Huperzine for Cognitive and Functional Impairment in Schizophrenia

A Phase 2 interventional study of placebo and huperzine 0.2 mg BID in Schizophrenia, sponsored by Biomedisyn Corporation. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2013-03-01.

Sponsored by Biomedisyn Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,466 studies in Schizophrenia with a site in United States — 149 open to participants now, 167 under way, 22 of them phase 3. Schizophrenia · United States.

Enrollment
745th of 1,320
56 · median 66
Started
2010
with 73 others
Phase 2
217 of 1,466
11 open now
Registered
484th of 1,466
by date

Among the 1,466 studies in Schizophrenia with a site in United States, this one is the 745th largest by enrollment of the 1,320 interventional ones that give a count, is one of 74 that started in 2010, is one of 217 in phase 2, and was the 484th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

149 of the 1,466 studies in Schizophrenia with a site in United States are open now. Recruiting first, the newest first:

144 more — sign in →

All 149 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,466 studies in Schizophrenia with a site in United States, or all of them as a file.
02

Study summary

Huperzine is a natural plant product with procognitive properties in patients with Alzheimer's disease. Cognitive difficulties hamper functioning in schizophrenia as well. The present study will investigate whether huperzine improves cognition and functioning in patients with schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • schizophrenia
  • cognition
  • functioning
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Psychiatric diagnosis of schizophrenia according to SCID-IV.
  2. Currently treated with an antipsychotic medication.
  3. Has tolerated current antipsychotic treatment adequately.
  4. Has received an adequate trial of antipsychotic (a least 3 months of at least 300 mg/d CPZ equivalent).
  5. Has been receiving current psychotropic medication (s) for at least 8 weeks.
  6. Has been receiving current doses of psychotropic medication (s) for at least 4 weeks.
  7. Has been clinically stable for at least 12 weeks.
  8. No more than moderate severity (4 on the 1-7 scale) on any PANSS positive item.
  9. No more than 15 on the total of PANSS negative symptom items.
  10. Simpson-Angus Scale total score \<7.
  11. Calgary Depression Scale for Schizophrenia total score \<11.
  12. Submaximal performance on at least one of the following MATRICS components (letter-number span \<20 OR HVLT total \<31 OR CPT d-prime \< 3.47).
  13. Score > 1 SD below age-, gender-, and education-adjusted normal control mean on MATRICS composite
  14. Good general health with no additional diseases expected to interfere with the studies.
  15. Fluent in English.
  16. Age 18-55.
  17. Adequate visual and auditory acuity to allow neuropsychological testing.
  18. Able to ingest oral medication.
  19. Not pregnant or lactating (women of must use a medically accepted method of ).
  20. Onset of schizophrenia prior to age 45.
  21. Available informant knowledgeable about subject's current functioning.
  22. obtained from the subject prior to entry into the study.

Exclusion criteria

Exclusion Criteria:

  1. Poor reading skills (raw score on MATRICS Wechsler Test of Adult Reading \< 6).
  2. History of systemic cancer within 5 years.
  3. Use of any drugs within 30 days prior to the screening visit.
  4. Use of cholinesterase inhibitors (galantamine, rivastigmine, donepezil, or tacrine) within 4 weeks of screening.
  5. Any laboratory test abnormality on screening tests (hematology, chemistry, urinalysis, ). Clinically significant LFT elevations will be defined as >2x the .
  6. Any significant neurologic disease including Alzheimer's disease, parkinson's disease, stroke, huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, history of head injury with loss of consciousness for greater than one day within the past 5 years, or with residual deficits.
  7. Use of antihypertensive agents with frequent CNS side effects (e.g. clonidine, propranolol) within 4 weeks prior to the screening visit.
  8. Use of medications known to alter drug absorption or metabolism (e.g. probenecid, cimetidine, anti-fungal agents, erythromycin, rifampin, and anticonvulsants) within 4 weeks prior to the screening visit.
  9. History of peptic ulcer disease within 2 years.
  10. History of myocardial infarction, significant cardiovascular disease, or congestive heart failure within 6 months, history of hepatic or renal insufficiency, insulin-requiring diabetes or uncontrolled diabetes mellitus.
  11. Clinically significant cardiac arrhythmia, resting pulse less than 50.
  12. Present use or use in the 4 weeks prior to screening of anti-parkinsonian or anticholinergic medications (e.g. Sinemet, amantadine, bromocriptine, pergolide, selegiline, atropine, scopolamine, benztropine, trihexyphenidyl, hydroxyzine, diphenhydramine).
  13. Use of narcotic analgesics within 4 weeks prior to the screening visit.
  14. History of alcohol or substance abuse or dependence within the past 2 years ( criteria).
  15. Receiving CYP 1A2 inhibitors such as certain SSRIs (all excluded in #4) cimetidine, methoxsalen, quinolones, furafylline, or moclobemide.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
56 participants (actual)

Study arms

  • Placebo comparator
    placebo

    Drug: placebo

  • Experimental
    huperzine 0.2 mg BID

    Drug: huperzine 0.2 mg BID

  • Experimental
    huperzine 0.4 mg BID

    Drug: huperzine 0.4 mg BID

  • Experimental
    huperzine 0.8 mg BID

    Drug: huperzine 0.8 mg BID

Interventions

  • Drugplacebo

    matching pill placebo

  • Drughuperzine 0.2 mg BID

    huperzine rising doses up to 0.2 mg BID

  • Drughuperzine 0.4 mg BID

    huperzine rising doses up to 0.4 mg BID

  • Drughuperzine 0.8 mg BID

    huperzine rising doses up to 0.8 mg BID

06

What researchers measure

Primary outcomes

  1. MATRICS battery

    Time frame: 26 weeks

Secondary outcomes

  1. UPSA

    Time frame: 26 weeks

07

Study locations

1 site
  • Yale University School of Medicine
    New Haven, Connecticut 06519, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2009
First posted
Aug 24, 2009
Start
Mar 2010
Primary completionActual
Dec 2012
CompletionActual
Dec 2012
Last update
Mar 1, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00963846
Lead sponsor
Biomedisyn Corporation
Collaborators
Yale University
Responsible party
Scott Woods, MD (Consultant, Biomedisyn Corporation) — Principal investigator
First posted
Aug 24, 2009
Start date
Mar 2010
Primary completion
Dec 2012
Completion
Dec 2012
Last update
Mar 1, 2013

Study contacts

Scott W Woods, MD
principal investigator · Biomedisyn Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion